Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Carbocysteine
Pinewood Laboratories Ltd
R05CB; R05CB03
Carbocysteine
250 mg/5ml
Oral solution
Product not subject to medical prescription
Mucolytics; carbocisteine
Marketed
1986-10-15
148 148 210 210 Package Leaflet: Information for the user Viscolex Syrup 250 mg / 5 ml Oral Solution Carbocisteine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse. What is in this leaflet: 1. What Viscolex Syrup is and what it is used for. 2. What you need to know before you take Viscolex Syrup. 3. How to take Viscolex Syrup. 4. Possible side effects. 5. How to store Viscolex Syrup. 6. Contents of the pack and other information. 1. What Viscolex Syrup is and what it is used for Viscolex Syrup is used to help treat lower respiratory tract disorders (disorders of the breathing passages) where the lungs produce too much mucus or the mucus is too thick. It contains carbocisteine which is a mucolytic agent that is used to dissolve and break down thick mucous in conditions such as chronic asthma or bronchitis. 2. What you need to know before you take Viscolex Syrup Do not take Viscolex Syrup: • If you are allergic to carbocisteine or any of the other ingredients of this medicine (listed in section 6). • If you have an active peptic ulcer. • Do not give to children under 2 years of age. Warnings and precautions Talk to your doctor or pharmacist before taking Viscolex Syrup: • If you are an older patient • If you have a history of gastrointestinal ulcers • If you are taking medication known to cause gastrointestinal bleeding • If you have a history of peptic ulcer • If you are on a low sodium diet • If you have a rare hereditary fructose intolerance or an intolerance to some sugars. Other m Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Viscolex Syrup 250 mg / 5 ml Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5 ml of oral solution contains carbocisteine 250 mg. _Excipients_ Each 5 ml contains: 3 g sucrose, 0.625 mg sunset yellow (E110), 4.5 mg sodium methyl parahydroxybenzoate (E219), 0.9 mg sodium ethyl parahydroxybenzoate (E215), 0.6 mg sodium propyl parahydroxybenzoate (E217) and <15 mg ethanol. For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral solution. Clear, yellow, oral solution with odour and flavour of orange. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Viscolex Syrup is a mucolytic agent indicated in children over the age of 2 and also in adults. It is an adjunctive therapy in lower respiratory tract disorders characterised by excessive viscous mucous. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults_ The usual dosage is 15ml (750mg) 3 times daily initially, reducing to 10ml (500mg) 3 times daily when a satisfactory response has been obtained. _Children_ 6 – 12 years: The usual dosage is 5ml (250mg) two to three times daily. 2 – 5 years: The usual dose is 2.5ml (125mg) three times daily. _Under 2 years_ Not recommended. 4.3 CONTRAINDICATIONS Hypersensitivity to carbocisteine or any of the excipients listed in section 6.1. Patients with active peptic ulceration. Children under 2 years of age. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _3_ _1_ _/_ _0_ _1_ _/_ _2_ _0_ _1_ _7_ _C_ _R_ _ Read the complete document